Stock Watch: Reclassified Revenues Help Novartis's Fourth Quarter
Last-Minute Revenue Reclassifications Are Probably Not Reproducible
Executive Summary
A one-off revenue rabbit brought out of the hat may have helped Novartis's fourth-quarter sales but its analysts and investors were not impressed.
You may also be interested in...
Stock Watch: Johnson & Johnson's Fast And Slow Lanes
With all the commentary on J&J’s acquisition strategy and its consumer spin-off, the fourth-quarter performance of its pharmaceutical division went almost unnoticed.
Novartis Opts For Alliance Rather Than Acquisition With Alnylam
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.